Aphria RX (Tilray Deutschland)
German medical cannabis producer and one of the first three domestic cultivation licensees, now operating as Tilray's German arm.
Aphria RX is a real, documented part of Germany's medical cannabis supply chain — one of only three companies that won the original BfArM domestic cultivation tender in 2019. It's now wholly owned by Tilray Brands. That's the verifiable core. Everything else marketed around the brand — yields, cultivar quality, pharmacy availability of specific SKUs — changes constantly and should be checked against current pharmacy listings and Tilray's investor disclosures rather than taken from third-party blog posts.
What it is
Aphria RX GmbH (now operating under Tilray's German organisation, Tilray Deutschland GmbH) is a German medical cannabis producer headquartered in Neumünster, Schleswig-Holstein. In April 2019 it was one of three companies awarded contracts under the German Federal Institute for Drugs and Medical Devices (BfArM) tender to cultivate medical cannabis domestically [1][2]. The other two original awardees were Aurora's German subsidiary and Demecan [2][3]. Before that point, all medical cannabis dispensed in German pharmacies had to be imported.
The BfArM tender allocated a fixed multi-year cultivation quota across 13 lots, with Aphria RX receiving five of them — the largest single share at award [1][2]. Strong evidence
Ownership and corporate structure
Aphria RX was originally the German subsidiary of Canadian licensed producer Aphria Inc. In May 2021, Aphria Inc. and Tilray Inc. completed a reverse-merger that operates under the Tilray Brands name, with the combined company headquartered for accounting purposes through Tilray [4][5]. As a result, Aphria RX is today a wholly-owned subsidiary of Tilray Brands, Inc. (NASDAQ/TSX: TLRY) and is generally presented to the German market under the Tilray Deutschland identity [5][6].
Readers should note that Tilray's European footprint also includes a separate EU-GMP facility in Cantanhede, Portugal, which supplies product across multiple European markets [6]. The Neumünster site is specifically the domestic German cultivation operation.
Market and category focus
Aphria RX operates strictly in the medical channel. Under the BfArM contract, harvested flower is sold to the Cannabisagentur (the cannabis agency within BfArM), which then distributes it to wholesalers and pharmacies at a regulated price [1][7]. Tilray also imports additional cannabis cultivars into Germany from its Canadian and Portuguese operations, distributed via the same wholesale/pharmacy chain [6].
After Germany's partial legalisation reform (CanG, effective 1 April 2024) and the reclassification of medical cannabis off the BtMG narcotics list, the medical market expanded significantly, with telemedicine prescriptions becoming a major demand driver [8]. Aphria RX, as a domestic cultivator, sits inside that supply chain but the share of domestic vs imported product in the overall German market remains weighted toward imports. Strong evidence
Notable products and services
Tilray markets dried-flower SKUs in Germany under both legacy Aphria and Tilray brand names, with cultivar names rotating over time. Historical and current examples documented in pharmacy listings include strains in the Tilray-branded medical line and domestically-grown German flower from the Neumünster facility [6][8]. We are deliberately not listing specific cultivar names, THC/CBD percentages, or batch identifiers here, because these change frequently and should be verified against current pharmacy data (e.g. ABDA / Lauer-Taxe listings) or Tilray's own German product pages at the time of prescription.
This article does not recommend any specific product. Whether a given Aphria RX or Tilray Deutschland SKU is appropriate is a clinical decision between a patient and a prescribing physician.
Reputation, controversies and regulatory context
Aphria RX's primary reputational anchor is simply being one of the three winners of the BfArM tender — a competitive, multi-year procurement process [1][2]. Beyond that, awards and accolades sometimes circulated in cannabis marketing materials should be treated with caution; Weedpedia does not verify trade-show awards as evidence of product quality.
The parent companies (Aphria Inc. and later Tilray Brands) have been the subject of investor litigation and short-seller reports unrelated to the German operation, including a 2018 Quintessential Capital / Hindenburg Research report on Aphria's Latin American acquisitions that triggered SEC-style scrutiny and a class action [9]. Tilray Brands has also faced shareholder lawsuits at various points concerning disclosures around mergers and forecasts [5]. None of these matters establish wrongdoing by the Neumünster cultivation entity specifically, but they are part of the public record on the parent group. Strong evidence
We are not aware, as of the last-checked date below, of any public regulatory finding against Aphria RX itself relating to product safety or its BfArM contract. Readers should treat absence of evidence as just that — not as a guarantee.
Availability and legal-market notes
Aphria RX / Tilray Deutschland product is available in Germany on prescription through pharmacies. It is not sold direct-to-consumer, is not part of the adult-use Cannabis Social Club system created by the 2024 CanG law, and is not legally exported to consumers in other countries [7][8]. Any website offering to ship "Aphria" or "Tilray" medical flower across borders to private buyers is operating outside the legal framework.
Following CanG, medical cannabis is no longer classified as a narcotic in Germany, which simplified prescribing but did not change the licensed-producer model that Aphria RX operates within [8].
What to verify before relying on brand claims
Before relying on any specific claim about this brand:
- Current ownership: confirm via Tilray Brands' most recent annual report or 10-K filing [5].
- Specific cultivars and cannabinoid content: check the current pharmacy/wholesaler database (e.g. Lauer-Taxe) or the official Tilray Deutschland medical portal — not third-party reviews.
- BfArM quota status: the original 2019 award covered a multi-year window; current cultivation volumes are not necessarily the same.
- Marketing claims about "award-winning" genetics or quality grades: these are not verified by BfArM. The agency contracts on supply and quality control, not on consumer-facing awards.
Last checked: 2025.
Sources
- Government Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Cannabisagentur — information on the German domestic cultivation tender and contract awardees.
- Reported Reuters, 'Germany awards first licences to grow medical cannabis,' 17 April 2019.
- Reported Marijuana Business Daily / MJBizDaily, coverage of the 2019 BfArM tender awards to Aphria, Aurora and Demecan.
- Reported Reuters, 'Tilray, Aphria close merger to form world's biggest cannabis firm,' 3 May 2021.
- Government Tilray Brands, Inc., Annual Report on Form 10-K, U.S. Securities and Exchange Commission filings.
- Reported Tilray Brands corporate website, Tilray Medical / Europe operations description.
- Government Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), 'Cannabis as medicine' overview, including the regulated supply and pricing through the Cannabisagentur.
- Reported MJBizDaily and Reuters coverage of Germany's 2024 Cannabis Act (CanG) and its impact on medical cannabis prescribing and supply.
- Reported Reuters, 'Aphria shares plunge after short-seller report alleges overpaying for assets,' 3 December 2018.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Aurora Cannabis — Canadian licensed producer focused on medical cannabis at home and a major exporter to Eur...
- Tilray Brands — A multinational cannabis and beverage company formed by the 2021 merger of Tilray and Aphr...